Importantly, subsequent analyses are warranted in order to assess whether the magnitude of the observed clinical response to BRAF and MAP2K inhibitors in the respective studies is correlated with the degree of autophagy activity in responding and nonresponding thyroid tumors. This evidence concerns the gene BRAF and thyroid tumor.